This page lists the cancer care hospitals in our directory offering Gallbladder Cancer Treatment in Bengaluru, India, including Narayana Health, Manipal Hospitals, HCG Cancer Centre, Medicover Hospital, Bangalore and others. Each listing links through to the hospital's full profile page.
Ask us about gallbladder cancer treatment in Bengaluru, India
Share a few details and our care coordination team will get back to you with next steps.
Compare 11 accredited hospitals for Cancer Care in Bengaluru, India
Featured🇮🇳 Narayana Health
Ranks #1 in this list by listed rating (4.8/5 from 1750 reviews).
🇮🇳 Manipal Hospitals
Ranks #2 in this list by listed rating (4.7/5 from 1450 reviews).
🇮🇳 HCG Cancer Centre
Ranks #3 in this list by listed rating (4.7/5 from 18 reviews).
🇮🇳 Medicover Hospital, Bangalore
Ranks #4 in this list by listed rating (4.7/5 from 68 reviews).
🇮🇳 Gleneagles Hospitals, Bengaluru
Ranks #5 in this list by listed rating (4.7/5 from 142 reviews).
🇮🇳 Manipal Hospital Malleshwaram (Northside)
Ranks #6 in this list by listed rating (4.6/5 from 71 reviews).
🇮🇳 Manipal Hospital, Old Airport Road
Ranks #7 in this list by listed rating (4.5/5 from 87 reviews).
🇮🇳 Manipal Hospital Yeshwanthpur (Columbia Asia)
Ranks #8 in this list by listed rating (4.5/5 from 98 reviews).
🇮🇳 Manipal Hospital Millers Road (Vikram Hospital)
Ranks #9 in this list by listed rating (4.4/5 from 74 reviews).
🇮🇳 Apollo Hospital, Bannerghatta Road
Ranks #10 in this list by listed rating (4.2/5 from 25 reviews).
🇮🇳 Fortis Hospital, Bannerghatta Road
Ranks #11 in this list by listed rating (4.2/5 from 58 reviews).
How we selected these hospitals
A hospital appears on this page when Cancer Care is among its listed specialties and it is located in Bengaluru, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Gallbladder Cancer Treatment in Bengaluru, India?
Choosing the right hospital for gallbladder cancer treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include cancer care rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Gallbladder Cancer Treatment
Gallbladder cancer is a rare but aggressive malignancy requiring precise, multidisciplinary oncological care — from radical cholecystectomy and extended hepatic resection to adjuvant chemotherapy with gemcitabine-cisplatin regimens and targeted immunotherapy. With 5-year survival rates ranging from 15% to 80% depending on staging, early and expert intervention is critical. GAF Healthcare connects international patients with India's and the UAE's leading JCI- and NABH/DHA-accredited cancer centres, where high-volume hepatobiliary oncology teams deliver globally benchmarked outcomes at a fraction of Western costs. Hospital Stay: 7–14 days (depending on surgical extent and post-operative recovery) • Total Stay in Country (Fit-to-Fly): 4–8 weeks (varies by surgical complexity, adjuvant therapy initiation, and wound healing status) • Success Rate: Stage I: ~80% 5-year survival; Stage II: ~40–55%; Stage III: ~15–25%; overall resection rate in high-volume centres: ~70–85% margin-negative (R0)
Clinical Overview
Gallbladder cancer (GBC) is an epithelial malignancy arising from the mucosal lining of the gallbladder, with adenocarcinoma accounting for over 90% of cases. It is the most common biliary tract cancer globally, with disproportionately high incidence in South Asia, Latin America, and Eastern Europe. The gallbladder's thin walls and proximity to the liver (segment IV–V), bile ducts, portal vasculature, and regional lymphatics mean that even early-stage tumours can invade adjacent structures, making anatomical staging — using the AJCC/TNM 8th Edition classification — and radiological precision essential to treatment planning. Physiologically, the disease frequently presents late due to the gallbladder's lack of a serosal layer on its hepatic surface, allowing direct hepatic extension without peritoneal dissemination, and its rich lymphatic drainage accelerating nodal spread. Standard of care is guided by tumour stage, resectability, and performance status (ECOG 0–2). For localised, resectable disease (T1b–T3), surgical resection remains the only curative modality. This typically involves radical cholecystectomy with en-bloc resection of liver segments IVb and V (2–3 cm hepatic margin), regional lymphadenectomy (portal hepatis nodes, pericholedochal, right celiac axis), and — when indicated — bile duct excision with hepaticojejunostomy reconstruction. For borderline or locally advanced cases, neoadjuvant chemotherapy with gemcitabine plus cisplatin (GemCis) or FOLFOX is increasingly employed to downstage tumours prior to resection. Unresectable or metastatic GBC is managed with systemic chemotherapy, and since 2022, durvalumab (an anti-PD-L1 checkpoint inhibitor) added to GemCis has become a first-line standard following the TOPAZ-1 trial, improving median overall survival to 12.8 months. Modern GBC management demands hepatobiliary HPB surgeons, interventional radiologists, molecular pathologists, and medical oncologists working in concert. High-volume centres in India and the UAE now integrate FIGO/ESMO-aligned tumour boards, next-generation sequencing (NGS) for actionable mutations (ERBB2, IDH1, FGFR2, BRAF), and advanced imaging protocols (gadoxetate-enhanced MRI, 18F-FDG PET-CT) to individualise therapy. This institutional sophistication, combined with dramatically lower cost structures, makes both India and the UAE compelling destinations for international patients.
Who is a Candidate?
• ELIGIBLE FOR SURGICAL RESECTION: • Histologically confirmed gallbladder carcinoma (adenocarcinoma, papillary, mucinous variants) staged T1b to T3 (AJCC 8th Edition) • ECOG performance status 0–2 • Adequate hepatic reserve: future liver remnant (FLR) ≥30% of total functional liver volume (assessed by CT volumetry) • No distant metastases (M0) on staging workup • No encasement of main portal vein or hepatic artery (or technically reconstructible involvement) • CA 19-9 and CEA within oncologically acceptable parameters relative to disease burden • CANDIDATES FOR NEOADJUVANT / BORDERLINE RESECTABLE PROTOCOLS: • T3–T4 disease with portal vein or bile duct involvement amenable to downstaging • Incidentally discovered GBC post-cholecystectomy (T1b or higher) requiring re-resection • REQUIRED DIAGNOSTIC WORK-UP PRIOR TO TRAVEL: • High-resolution contrast-enhanced CT (chest, abdomen, pelvis) — triple-phase protocol • MRI/MRCP (gadoxetate-enhanced) for hepatic parenchymal and biliary anatomy • 18F-FDG PET-CT scan for nodal and occult metastatic disease • Endoscopic ultrasound (EUS) for regional lymph node staging if CT-equivocal • Liver function tests, coagulation profile (INR, PT), full blood count, metabolic panel • Tumour markers: CA 19-9, CEA, AFP • Next-generation sequencing (NGS) or tumour molecular profiling (ERBB2, FGFR, IDH1, BRAF, MSI/MMR) — increasingly standard at GAF partner centres • Histopathology report with IHC panel (CK7, CK20, CDX2, p53) • ECHO (echocardiogram) and pulmonary function tests (PFTs) pre-operatively, especially for patients >60 or with cardiac history • CONTRAINDICATIONS / EXCLUSION CRITERIA: • Stage IVB disease (distant organ metastases not amenable to curative-intent resection) • Peritoneal carcinomatosis (relative contraindication; some centres offer HIPEC in select cases) • Child-Pugh C cirrhosis or severe hepatic dysfunction • ECOG performance status ≥3 • Active uncontrolled infection, bleeding diathesis, or prohibitive cardiopulmonary comorbidity • Prior biliary stenting causing peritoneal seeding (port-site or bile spillage in prior laparoscopic cholecystectomy — must be declared and assessed)
Treatment Options & Approaches
SURGICAL APPROACHES: 1. SIMPLE CHOLECYSTECTOMY (T1a only): Acceptable for incidental T1a tumours confined to the lamina propria with clear margins on frozen section. Laparoscopic technique is standard. No re-resection required. 2. RADICAL CHOLECYSTECTOMY WITH HEPATIC RESECTION (T1b–T3, primary standard): En-bloc resection of the gallbladder with a 2–3 cm margin of hepatic parenchyma involving segments IVb and V. Accompanied by systematic lymphadenectomy of the hepatoduodenal ligament (portal hepatis), including pericholedochal, cystic duct, right hepatic artery, and anterior/posterior portal vein nodes (minimum 6 nodes for adequate staging). Bile duct excision with Roux-en-Y hepaticojejunostomy reconstruction is added when bile duct margin involvement is confirmed on frozen section or when achieving a clear cystic duct margin is not feasible. 3. EXTENDED HEPATIC RESECTION (T3–T4 with vascular or extensive hepatic involvement): Right hepatectomy or right trisectionectomy may be required for advanced local disease. Portal vein embolisation (PVE) is performed 4–6 weeks pre-operatively when FLR is inadequate (<30%). In selected centres, associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is employed. 4. MINIMALLY INVASIVE / ROBOTIC SURGERY: Laparoscopic and robotic-assisted radical cholecystectomy (da Vinci Xi system) are performed at high-volume Indian and UAE centres for appropriately selected patients (T1b–T2, no vascular involvement). Robotic platforms offer superior 3D visualisation, wristed instrument articulation, and tremor filtration — particularly advantageous for precise hepatic parenchymal dissection and lymphadenectomy in the hepatoduodenal ligament. Published data show equivalent oncological outcomes with significantly reduced blood loss, shorter hospital stays, and faster return to systemic therapy eligibility. 5. PALLIATIVE / NON-SURGICAL INTERVENTIONS: • Biliary drainage: Endoscopic retrograde cholangiopancreatography (ERCP) with plastic or metal stent insertion, or percutaneous transhepatic biliary drainage (PTBD) for obstructive jaundice in unresectable cases • Transarterial chemoembolisation (TACE): Used in select unresectable cases with predominantly hepatic disease • Stereotactic body radiotherapy (SBRT): Increasingly used for local control in unresectable or oligometastatic GBC at specialised centres • Photodynamic therapy (PDT): For intraluminal biliary palliation at select centres SYSTEMIC THERAPY PROTOCOLS: • First-Line (Advanced/Metastatic): Gemcitabine 1000 mg/m² + Cisplatin 25 mg/m² (Days 1, 8 every 21 days) + Durvalumab 1500 mg (Day 1 every 21 days) — TOPAZ-1 regimen; now standard of care per ESMO/ASCO 2023 guidelines • Alternatively: FOLFOX (oxaliplatin + leucovorin + 5-FU) as per ABC-06 trial for second-line or cisplatin-ineligible patients • Adjuvant Chemotherapy: Capecitabine monotherapy for 6 months post-resection (BILCAP trial) is the current standard for R0/R1 resected patients • Targeted Therapy: ERBB2 (HER2) amplification (~15–20% of GBC) — trastuzumab-based regimens or tucatinib combinations under investigation; IDH1 mutations — ivosidenib; FGFR alterations — pemigatinib or infigratinib; BRAF V600E — dabrafenib + trametinib • Immunotherapy: Pembrolizumab for MSI-H/dMMR tumours (TMB-H); Nivolumab combinations in clinical trials • Tumour Mutational Burden (TMB) and PD-L1 expression guide immunotherapy eligibility RADIATION THERAPY: • External beam radiotherapy (EBRT) with concurrent capecitabine or 5-FU for R1 resection margins or unresectable local disease • Intensity-modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT) are available at partner centres, offering precise dose delivery with sparing of adjacent bowel and liver
Recovery
PHASE 1 — PRE-TRAVEL WORKUP (2–4 weeks before departure): • Patient submits medical records to GAF Healthcare case manager: histopathology, imaging (CT/MRI/PET-CT), blood reports, operative reports if prior cholecystectomy • GAF connects patient with assigned hepatobiliary oncology team at chosen centre (India or UAE) • Telemedicine consultation conducted: tumour board review, resectability assessment, staging confirmation, NGS report review • Travel plan confirmed: visa category arranged (e-Medical Visa for India; visit/medical visa for UAE), treatment dates locked • Insurance pre-authorisation initiated where applicable PHASE 2 — ARRIVAL & PRE-OPERATIVE EVALUATION (Days 1–3 in-country): • Airport pickup by GAF-assigned driver; check-in to partner hospital or accommodation • Repeat or supplementary imaging at destination centre if required (gadoxetate MRI, EUS) • Anaesthesiology and cardiology pre-operative clearance; ECHO, spirometry, coagulation studies • Tumour board conference — surgical and medical oncology alignment • Nutritional assessment; high-protein pre-operative nutrition protocol initiated (ERAS — Enhanced Recovery After Surgery pathway) • Biliary drainage (PTBD or ERCP stenting) if pre-operative jaundice present and bilirubin >3 mg/dL • PVE performed if FLR inadequate (4–6 week wait period may be required before major hepatic resection) • Informed consent; anaesthesia discussion PHASE 3 — SURGICAL PROCEDURE (Day 3–5): • General anaesthesia; intraoperative ultrasound to confirm hepatic margins and vascular anatomy • Radical cholecystectomy with hepatic resection (laparoscopic/robotic or open, per plan); operative time typically 3–6 hours • Intraoperative frozen section of cystic duct and hepatic margins to confirm R0 resection • Systematic lymphadenectomy; bile duct excision + hepaticojejunostomy if indicated • Abdominal drain placement; closure PHASE 4 — EARLY POST-OPERATIVE RECOVERY (Days 1–7 post-surgery): • ICU or HDU monitoring for 24–48 hours; liver function monitoring, drain output, fluid balance • Enhanced Recovery After Surgery (ERAS) protocol: early mobilisation Day 1, liquid diet by Day 2, soft diet by Day 3 • IV analgesia transitioned to oral; anti-nausea and proton pump inhibitor (PPI) medications • Deep vein thrombosis (DVT) prophylaxis: LMWH injections and compression stockings from Day 1 • Drain removed Day 4–7 when output <100 mL/day (bilious or serous) • For robotic/laparoscopic cases: discharge typically Day 5–7; open major hepatectomy: Day 8–12 PHASE 5 — IN-COUNTRY RECOVERY & ADJUVANT THERAPY INITIATION (Weeks 2–6): • Weekly outpatient oncology reviews; wound check, LFT monitoring, CA 19-9 trending • Post-operative restaging CT/MRI at Week 4–6 to confirm R0 status and detect early recurrence • Adjuvant capecitabine initiated typically 6–8 weeks post-operatively in R0/R1 resected patients • First cycle of systemic chemotherapy (if required) may be administered at the treating centre before departure • Nutritional counselling, physiotherapy, and hepatology follow-up • Psychological support and survivorship care planning provided by GAF partner centres PHASE 6 — FIT-TO-FLY CLEARANCE & DEPARTURE (Weeks 4–8): • Fit-to-fly assessed by treating surgical and oncology team based on: wound healing, drain removal, absence of bile leak or hepatic insufficiency, stable LFTs, DVT prophylaxis completion, and patient mobility • Straightforward radical cholecystectomy (laparoscopic): fit-to-fly at 4–5 weeks • Major open hepatic resection: fit-to-fly at 6–8 weeks • Comprehensive discharge summary, imaging CDs, pathology blocks, and ongoing chemotherapy protocol provided for home oncologist • GAF Healthcare facilitates telemedicine follow-up at 1 month, 3 months, and 6 months post-discharge
Risks to be aware of
Gallbladder cancer surgery, particularly when involving extended hepatic resection and biliary reconstruction, carries a defined spectrum of perioperative and oncological risks that patients must understand before travel. Perioperative mortality at high-volume HPB centres ranges from 1–3% for standard radical cholecystectomy and up to 5–8% for major hepatectomy, with rates significantly lower at centres performing >20 hepatobiliary resections per month. The most significant surgical complication is post-hepatectomy liver failure (PHLF), graded using the ISGLS criteria, occurring in 5–10% of cases involving resection of >60% of hepatic parenchyma — mitigated by pre-operative FLR volumetry and portal vein embolisation when indicated. Bile leak (ISGLS Grade B/C) occurs in 5–15% of cases, typically managed conservatively with drain maintenance or radiological/endoscopic intervention. Post-operative haemorrhage requiring re-exploration occurs in 1–3% of patients. Hepaticojejunostomy anastomotic stricture is a delayed complication (6–24 months post-operatively) occurring in approximately 3–8% of reconstructed cases, managed with endoscopic balloon dilation or percutaneous interventions. Systemic chemotherapy with gemcitabine-cisplatin carries well-documented risks of myelosuppression (Grade 3/4 neutropaenia in 25–30%), nephrotoxicity (managed with vigorous pre-hydration), and peripheral neuropathy. Durvalumab and other checkpoint inhibitors carry immune-related adverse events (irAEs), including immune-mediated hepatitis (Grade ≥3 in 3–5%), colitis, and pneumonitis, requiring early recognition and corticosteroid management. Oncologically, even R0 resections carry substantial recurrence risk: approximately 60–70% of patients develop locoregional or distant recurrence within 2 years, emphasising the importance of structured adjuvant therapy and surveillance imaging (CT/MRI every 3–6 months for 2 years). Patients with bile spillage during prior laparoscopic cholecystectomy face elevated risk of peritoneal seeding; port-site excision is recommended and outcomes in this subgroup are generally poorer. GAF Healthcare ensures patients receive complete risk stratification, pre-operative optimisation, and written informed consent documentation from their treating HPB oncologist before committing to travel.
Why GAF Healthcare
GAF Healthcare provides end-to-end non-medical coordination for gallbladder cancer patients travelling to India or the UAE, ensuring the treatment experience is seamless from the moment of enquiry to post-discharge follow-up. INDIA — VISA & ENTRY: GAF Healthcare facilitates the e-Medical Visa application for India, which is available to nationals of over 170 countries. The e-Medical Visa allows a stay of up to 60 days (extendable) and permits two accompanying attendants under the e-Medical Attendant Visa category. Processing typically takes 3–5 business days. GAF's documentation team assists with hospital appointment letters, diagnostic summaries, and financial guarantees required by the Indian consulate or embassy. UAE — VISA & ENTRY: Nationals of over 50 countries receive visa-free or visa-on-arrival access to the UAE. For nationalities requiring a prior visa, GAF Healthcare coordinates the UAE Medical/Tourist Visa application through DHA-registered or MOHAP-approved treatment centres in Dubai and Abu Dhabi. Visa letters from accredited hospitals are arranged within 48–72 hours of treatment confirmation. AIRPORT TRANSFERS: Private, air-conditioned vehicle transfers are arranged for the patient and up to two attendants from the airport to the hospital or partner accommodation. For post-surgical discharge, medically equipped vehicles with trained attendants are provided where clinically indicated. DEDICATED CASE MANAGER & TRANSLATORS: Each patient is assigned a personal GAF Healthcare case manager who serves as a single point of contact throughout the treatment journey. For non-English-speaking patients, GAF provides professional medical interpreters in Arabic, Russian, French, Bengali, Swahili, and other languages — available in-person at the hospital or via secure video link for consultations. ACCOMMODATION FOR ATTENDANTS: GAF Healthcare arranges accommodation for up to two attendants in vetted partner guest houses, serviced apartments, or hospital-adjacent hotels within 1–2 km of the treating facility. Accommodation packages include daily housekeeping, Wi-Fi, and meal services. For patients at certain premium partner hospitals in India (e.g., Tata Memorial, Apollo, Fortis), attendant rooms within the hospital campus may be available. TELEMEDICINE & FOLLOW-UP COORDINATION: Post-discharge, GAF coordinates structured telemedicine consultations between the patient's home oncologist and the treating Indian or UAE-based team at 1-month, 3-month, and 6-month intervals. All pathology slides, imaging CDs, NGS reports, and treatment summaries are digitised and shared via a secure patient portal.
Common questions about Gallbladder Cancer Treatment
What is the cost of Gallbladder Cancer Treatment in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after Gallbladder Cancer Treatment?
What is the success rate of Gallbladder Cancer Treatment?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Gallbladder Cancer Treatment in Bengaluru, India
Discover the Top Hospitals for Gallbladder Cancer Treatment in Bengaluru, India
This page lists 11 accredited cancer care hospitals in Bengaluru, India, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about gallbladder cancer treatment in Bengaluru, India
How many cancer care hospitals are listed in Bengaluru, India?
How do you choose which hospitals to list?
How much does treatment cost in India?
Are there cancer care hospitals for this in other India cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for gallbladder cancer treatment in Bengaluru, India.
Contact us to report an inaccuracy on this page.